
|Articles|September 1, 2009
Gene-directed therapy in glaucoma may have future clinical applications
Application of genetic knowledge holds huge potential for the future and some believe that it has potential to become larger than the pharmaceutical market. Here Dr Alward examines what it has offered for the understanding and future treatment of glaucoma. Until recently, breakthroughs in glaucoma genetics emerged from painstaking family research, with the discovery of LOXL1 being the exception.
Advertisement
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times Europe
1
FLORetina 2025: Antithrombotic use examined in wet AMD submacular hemorrhage
2
FLORetina 2025: Remotely managing patients with neovascular age-related macular degeneration
3
FLORetina 2025: New horizons in research and risk management for ROP
4
FLORetina 2025: Artificial intelligence at the frontlines of ROP care
5













































